ClinicalTrials.gg
RecruitingNCT05776420VOUCH4DIABETESUpdated Feb 10, 2026

Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes

A Phase 3 interventional study of Food voucher in Diabete Type 2, sponsored by Unity Health Toronto. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Unity Health Toronto · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Diabetes Mellitus, Type 2 by Unity Health Toronto — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Unity Health Toronto.

Planned enrollment
Largest of 14
390 · median 94
Started
2023
the only one that year
Phase 3
Only one
of the 19
Registered
18th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by Unity Health Toronto, this one has the largest planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 19 studies in Diabetes Mellitus, Type 2 by Unity Health Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by Unity Health Toronto, or all of them as a file.
02

Study summary

This randomized controlled trial (RCT) will determine if access to a voucher for healthy foods reduces blood sugar levels among people living on a low income who have type 2 diabetes or elevated blood sugar.

03

Conditions studied

  • Diabete Type 2
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 6.0 to 11.0
  • report food insecurity or financial insecurity

Exclusion criteria

Exclusion Criteria:

  • live with a current study participant
  • \< 6 months
  • multiple life-threatening allergies to common foods
  • require total parenteral nutrion
  • blood dyscrasia that interferes with interpretation
  • hemoglobin A1c >11
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Food voucher

    $65 monthly voucher for healthy foods (phase 1)

    Behavioral: Food voucher

  • No intervention
    Control
  • Experimental
    Large voucher

    $160 monthly voucher for healthy foods (phase 2)

    Behavioral: Food voucher

  • Active comparator
    Small voucher

    $40 monthly voucher for healthy foods (phase 2)

    Behavioral: Food voucher

Interventions

  • BehavioralFood voucher

    A voucher of that can be redeemed for food at grocery stores.

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1c

    Change in hemoglobin A1c

    Time frame: 6 months

Secondary outcomes

  1. General health ("In general, how would you rate your health today?")

    Self-reported health. Potential responses are: very good, good, moderate, bad, very bad and decline to respond.

    Time frame: 6 months

  2. Financial security ("Do you have trouble making ends meet at the end of the month?")

    Self-reported financial security

    Time frame: 6 months

  3. Food insecurity measured by 6 questions from Household Food Security Survey

    Self-reported food insecurity

    Time frame: 6 months

  4. Fruit and vegetable consumption

    Self-reported fruit and vegetable consumption

    Time frame: 6 months

  5. Health care utilization using administrative data

    Includes hospitalizations, outpatient visits and primary care visits

    Time frame: 6 months

  6. Carotenoid level

    Serum caortenoid level

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • St Michael's Hospital Academic Family Health Team
    Toronto, Canada
    Recruiting
08

References and documents

Publications

  • Ul Haq MZ, Sinha L, Nwebube C, Buadu A, Sabir A, Persaud N. Experiences of people with diabetes receiving a voucher for healthy foods: a qualitative study. BMC Public Health. 2026 Feb 10;26(1):892. doi: 10.1186/s12889-026-26436-y. PubMed 41664067 ↗
  • Persaud N, Ul Haq MZ, Buadu A, Sabir A, Sinha L, Thorpe KE, Xu K, Hwang SW, Pinto AD, Gucciardi E. Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial. JAMA Intern Med. 2025 Dec 1;185(12):1434-1441. doi: 10.1001/jamainternmed.2025.5420. PubMed 41114992 ↗

Individual participant data

Plan to share: Yes — We plan to share de-identified individual participant data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Apr 2027, 48 months after the start.

Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 48 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Mar 20, 2023
StartActual
Mar 21, 2023
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05776420
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Mar 21, 2023
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Nav Persaud
Contact
nav.persaud@utoronto.ca
416-864-6060

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion